-
Product Insights
Overactive Bladder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder – Drugs In Development, 2022, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape. Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge...
-
Product Insights
Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glomerulonephritis is a disease of the kidney, characterized by inflammation of the glomeruli. Some factors that increase the chances of getting glomerulonephritis include a family history of glomerulonephritis, the presence of a known cause of glomerulonephritis, and high blood pressure. The Glomerulonephritis pipeline market research report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers...
-
Sector Analysis
Focal Segmental Glomerulosclerosis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Focal segmental glomerulosclerosis market research report includes an assessment of the disease epidemiology, late- to mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Focal segmental glomerulosclerosis (FSGS). The report also analyzes the clinical and commercial landscapes of FSGS, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment. Focal segmental glomerulosclerosis (FSGS) is a histological pattern of glomerular injury, rather than a single disease, which...
-
Sector Analysis
Chronic Kidney Disease Epidemiology Analysis and Forecast to 2031
The total prevalent cases of chronic kidney disease (CKD) were 103,485,844 cases in 2021 in the 7 major markets (7MM). The number of cases is expected to increase at an annual growth rate (AGR) of more than 1% during the forecast period. Chronic kidney disease or chronic renal disease, is a condition characterized by a gradual loss of kidney function over time. This leads to the accumulation of excess fluid and waste in the body. In the early stages, chronic...
-
Product Insights
Focal Segmental Glomerulosclerosis (FSGS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Focal Segmental Glomerulosclerosis (FSGS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Focal Segmental Glomerulosclerosis (FSGS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (FSGS), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history...
-
Product Insights
IgA Nephropathy (Bergers Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
IgA Nephropathy (Berger's Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the IgA Nephropathy (Berger's Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for IgA Nephropathy (Berger's Disease), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history...
-
Product Insights
Stress Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Stress Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Stress Urinary Incontinence pipeline landscape. The report provides comprehensive information on the therapeutics under development for Stress Urinary Incontinence, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news...
-
Product Insights
Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action...
-
Product Insights
Membranous Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Membranous Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Membranous Glomerulonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Membranous Glomerulonephritis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases....
-
Product Insights
Primary Hyperoxaluria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Primary Hyperoxaluria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Primary Hyperoxaluria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.